There was big news in the cannabis industry today as the FDA approved the second drug based on cannabis Insys Therapeutics.
The drug is called Syndros. dronabinol is a drug designed to treat conditions related to AIDS and cancer. Two years ago, the FDA rejected Syndros. On July 5, 2016, the FDA officially approved the drug. After the announcement, shares INSYS Therapeutics rose 29%.
Syndros was specifically approved by the FDA for the treatment of anorexia associated with loss Weight in patients with AIDS. They also approved treat nausea and vomiting that occurs after cancer chemotherapy in patients who have not responded well to conventional treatments nausea management.
The FDA rejected Insys Therapeutics in October 2014 after the company filed a new drug application to the regulatory body. In June 2015, Insys Therapeutics resubmitted its new drug application and clearly worked.
Shares of the company (Insy) fell 62% in the year to Friday’s close after Insys reported lower first-quarter sales of your product for the treatment of cancer pain logo, Subsys. Those sales were below expectations of analysts.
How Syndros work?
Syndros is a liquid form of oral dronabinol, a drug used to treat nausea and vomiting caused by chemotherapy. It usually comes in the form of a capsule. It promotes appetite and reduces nausea working as cannabinoid .
is the first and only dronabinol solution approved by the FDA for oral use. It is also a big problem as it comes in the form of an easy to swallow liquid. And you do not need to be refrigerated for 28 days.
The dose can also be assessed for use in a clinical setting.
The drug works by specifically targeting the brain area that controls nausea, vomiting and appetite.
Typical side effects of dronabinol include weakness, stomach pain, nausea, vomiting, memory loss, anxiety and a feeling of “high”. There are also more serious side effects, including seizures or heart-rhythm risen.
Doctors often prescribe a low dose of dronabinol before increasing the dose as your body gets used. However, overdoses are other risks of the drug. Typically, dronabinol is sold under the brand name Marinol, which is available in 2.5 mg, 5 mg, 10 mg and capsules.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that, in the words of a press release announcing the news:
“develops and markets innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of life of patients. ”
The company is best known for its patented sublingual spray and pharmaceuticals cannabinoids. Subsys, the flagship product of the company, is a fentanyl sublingual spray that is currently on the market. Syndros, the oral dronabinol solution that has just been approved, is the second drug company has received approval from the FDA.